Business
Strategic Investment: CANSOUL acquires stake in SYNBIOTIC
Strategic Investment: CANSOUL acquires stake in SYNBIOTIC
About this update from Synbiotic Se
SYNBIOTIC SE/ Key word(s): Investment Strategic Investment: CANSOUL acquires stake in SYNBIOTIC 16.12.2025 / 11:49 CET/CESTThe issuer is solely responsible for the content of this announcement.Strategic Investment: CANSOUL acquires stake in SYNBIOTIC Düsseldorf, 16 December 2025 – The European medical cannabis and industrial hemp group SYNBIOTIC SE (ISIN: | WKN: A3E5A5) announces a strategic equity investment. The specialised cannabis and hemp equity fund CANSOUL – Hanf Aktien Global (WKN: A2PX8U | ISIN: ) has acquired a stake in SYNBIOTIC as part of a cash capital increase. CANSOUL is a specialised equity fund investing across the entire global value chain of the hemp and cannabis industry. Its holistic investment approach covers cultivation, research, technology, extraction and distribution through to pharmaceutical development. The fund invests globally in leading industry players and diversifies across medical cannabis, industrial hemp, CBD and — in legally regulated jurisdictions — the recreational market. CANSOUL’s objective is to identify early-stage trends in infrastructure, patents and licences that fundamentally drive long-term market development. Daniel Stehr, Founder of the CANSOUL Fund, commented: “Our decision to participate in the capital increase of SYNBIOTIC is based on an attractive fundamental valuation and the successful internal restructuring of the Group. SYNBIOTIC holds assets with strong strategic differentiation, including an import licence and GMP manufacturing authorisation for medical cannabis, as well as its shareholding in GOC Nexus with its patented cold plasma process for GMP sterilisation — a clear technological advantage in quality enhancement. Combined with market leadership in industrial hemp and a management team with deep regulatory expertise, SYNBIOTIC offers an attractive risk-return profile.” The transaction marks the starting point of a long-term partnership. As one of the leading players in regulated cannabis investments, CANSOUL underscores the attractiveness of SYNBIOTIC’s diversified business model. “The investment via the capital increase represents the beginning of a strategic engagement. The SYNBIOTIC position is now being built within the CANSOUL fund’s portfolio and is explicitly designed as a long-term investment to accompany the growth potential of the diversified platform over the coming years,” Stehr ...